Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss.
Oral contraceptive pretreatment facilitated scheduling of pure FSH/GnRH antagonist cycles but in a small subset of patients was associated with low serum LH levels, reduced ovarian response, and early pregnancy loss. Supplementation with LH could be examined as a possible way to improve cycle outcome.
Meldrum
David R
DR
Reproductive Partners Medical Group, Redondo Beach, California, USA. davidmeldrum@earthlink.net
Scott
Richard T
RT
Levy
Michael J
MJ
Alper
Michael M
MM
Noyes
Nicole
N
D000022:Abortion, Spontaneous / Q000209:etiology; D000328:Adult; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D003276:Contraceptives, Oral / Q000494:pharmacology*; D010064:Embryo Implantation; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D010053:Ovary / Q000187:drug effects*; D010062:Ovulation Induction; D011247:Pregnancy; D012372:ROC Curve; D011994:Recombinant Proteins / Q000494:pharmacology
D006063:Chorionic Gonadotropin; D003276:Contraceptives, Oral; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C061018:ganirelix